376 related articles for article (PubMed ID: 37109350)
1. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
Li Y; Wang X; Hou X; Ma X
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109350
[TBL] [Abstract][Full Text] [Related]
2. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
[No Abstract] [Full Text] [Related]
3. Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer.
Bian X; Sun C; Cheng J; Hong B
Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765210
[TBL] [Abstract][Full Text] [Related]
4. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
5. Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
Goff PH; Bhakuni R; Pulliam T; Lee JH; Hall ET; Nghiem P
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298632
[TBL] [Abstract][Full Text] [Related]
6. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
7. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.
Deng S; Vlatkovic T; Li M; Zhan T; Veldwijk MR; Herskind C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230796
[TBL] [Abstract][Full Text] [Related]
8. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
9. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.
Ronco C; Martin AR; Demange L; Benhida R
Medchemcomm; 2017 Feb; 8(2):295-319. PubMed ID: 30108746
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
12. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
13. Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
Staniszewska M; Iking J; Lückerath K; Hadaschik B; Herrmann K; Ferdinandus J; Fendler WP
Nucl Med Biol; 2021; 96-97():101-111. PubMed ID: 33866131
[TBL] [Abstract][Full Text] [Related]
14. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
Front Oncol; 2020; 10():581217. PubMed ID: 33224881
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M; Chen S; Ao D
MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
[TBL] [Abstract][Full Text] [Related]
16. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation.
Carlsen L; El-Deiry WS
Front Oncol; 2022; 12():998388. PubMed ID: 36276148
[TBL] [Abstract][Full Text] [Related]
19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
20. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
Mao X; Lee NK; Saad SE; Fong IL
Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
